ClinicalTrials.gg
CompletedNCT06508385Updated Oct 27, 2026

The Effect of Perception of Improvement in Patients With Fibromyalgia

An interventional study of Breathing exercise in Fibromyalgia, sponsored by Istanbul Medeniyet University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 25 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Istanbul Medeniyet University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Fibromyalgia with a site in Turkey — 50 open to participants now, 54 under way, none of them phase 3. Fibromyalgia · Turkey.

Enrollment
80th of 104
36 · median 52
Started
2024
with 27 others
No phase
102 of 195
25 open now
Registered
109th of 195
by date

Among the 195 studies in Fibromyalgia with a site in Turkey, this one is the 80th largest by enrollment of the 104 interventional ones that give a count, is one of 28 that started in 2024, is one of 102 with no phase, and was the 109th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

50 of the 195 studies in Fibromyalgia with a site in Turkey are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 25 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Fibromyalgia with a site in Turkey, or all of them as a file.
02

Study summary

Fibromyalgia (FM) is a chronic pain syndrome characterized by impaired perception, transmission, and processing of nociceptive stimuli and causing widespread pain. Pain in FM is the disease itself and is characterized by nociplastic pain that may occur independently of any peripheral nociceptor activity or be felt without disease or damage to the somatosensory system. It is thought that the pain processing process is disrupted due to the changing neurotransmitter release activity and this situation causes pain to be felt more in FM. Chronic pain is the result of perception alteration associated with nociceptive afferent information affecting the cortex; underlying this change are limbic emotional learning mechanisms. Numerous factors, including emotional state, attention, and past painful experiences, modulate nociceptive inputs with the activation of multiple brain regions, resulting in a personalized pain experience. The chronic pain management program should target the central nervous system rather than the peripheral tissues because pain originates in the sensitized nervous system. For this reason, it is important to include plasticity-oriented approaches, cortical disinhibition methods, and strategies for improving perception and behavior change, which aim to replace negative beliefs with positive beliefs, into clinical practice. Our project aims to investigate the effectiveness of the therapeutic intervention, which consists of patient education supported Neuro-Linguistic Programming (NLP), visual feedback and metaphor-assisted breathing therapy designed to provide a perception of improvement and presented in a virtual reality environment, on pain processing, pain intensity, pain-pressure threshold, psychosomatic reflections (biomechanical and viscoelastic properties of tissue, sleep quality, pain catastrophizing behavior, anxiety and depression), disease impact and quality of life in FM patients.

03

Conditions studied

  • Fibromyalgia

Keywords

  • functional brain activity
  • Pain
  • Tissue properties
04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosed with Fibromyalgia at least 1 year ago according to ACR criteria

Age range 25-55

Female

Scored at least 24 on the Mini-Mental State Assessment Test

Reported weekly pain intensity of at least 40 mm on the Visual Analog Scale

Be on a stable dose of medication for at least 6 months (serotonin norepinephrine reuptake inhibitors [e.g., duloxetine, milnacipran]; alpha 2-delta receptor ligand [e.g., pregabalin]; gabapentinoids)

Exclusion criteria

Exclusion Criteria:

Having inflammatory rheumatic disease, , neurological disease, connective tissue disease, severe anemia, uncontrolled endocrine diseases

(BMI) ≥ 30 Kg/m2

Being pregnant

Having inability to understand, read and speak Turkish

Having difficulty in hearing and seeing

Having any metallic or electronic device in the body that will create incompatibility with the magnetic field in the fMRI scan Having any disease diagnosis (serious psychotic disorder, delirium, mental retardation, epilepsy, heart disease, lung diseases, etc.) that may prevent participation in the evaluation and training to be conducted within the scope of the research

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Control Group

    NLP-supported patient education will be given and breath therapy will be applied to the Control Group

    Other: Breathing exercise

  • Experimental
    Virtual Reality Group-1

    NLP-supported patient education will be given. Visual feedback and metaphor-assisted breathing therapy over the three most painful points in the McGill-Melzack Pain Scale (real painful points) were given to this group in virtual reality environment.

    Other: Breathing exercise

  • Experimental
    Virtual Reality Group-2

    NLP-supported patient education will be given. Visual feedback and metaphor-assisted breathing therapy over the contralateral of the points reported as the three most painful points in the McGill-Melzack Pain Scale (virtual painful points) to this group in a virtual reality environment

    Other: Breathing exercise

Interventions

  • OtherBreathing exercise

    Breathing exercises will include; 1. Correct posture and sitting 2. Nose opening techniques 3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm 4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds).

06

What researchers measure

Primary outcomes

  1. Functional Magnetic Resonance

    The process of processing pain will be determined by functional magnetic resonance imaging performed immediately before and after the experimental pressure pain. ROI analysis will ve performed. No score is defined.

    Time frame: Measurement of changes from baseline process of processing pain will be measured at 6 week and 10 week

  2. Measurement of pain-pressure threshold

    Pain-pressure threshold evaluated with a pain threshold measuring device (Algometer).

    Time frame: Measurement of changes from baseline of pain-pressure threshold will be measured at 6 week and 10 week

Secondary outcomes

  1. Sleep Quality

    Sleep quality will be evaluated with Pittsburgh Sleep Quality Index. Score is between 0 (the best sleep quality) and 21 (the worst sleep quality)

    Time frame: Measurement of changes from baseline of sleep quality will be measured at 6 week and 10 week

  2. Functional status and disease impact

    Functional status and disease impact will be evaluated with Revised Fibromyalgia Impact Questionnaire. Score is between 0 (no disease impact and 100 (the highest disease impact)

    Time frame: Measurement of changes from baseline of functional status and disease impact will be measured at 6 week and 10 week.

  3. Quality of Life of patients

    Quality of Life will be measured with QOL Short Form 12. Score is between 0 (the lowest quality of life and 100 (the highest quality of life)

    Time frame: Measurement of changes from baseline of quality of life will be measured at 6 week and 10 week

  4. Anxiety and Depression Status

    Anxiety and Depression will be evaluated with Hospital Anxiety and Depression Scale. Score is between 0 (no anxiety and depression risk) and 21 (the highest anxiety and depression risk)

    Time frame: Measurement of changes from baseline of anxiety and depression status will be measured at 6 week and 10 week

  5. Pain catastrophizing behavior

    Assessing pain catastrophizing behavior will be evaluated with Pain Catastrophizing Scale. Score is between 0 (no pain catastrophizing behavior) and 52 (the highest pain catastrophizing behavior)

    Time frame: Measurement of changes from baseline of changes from baseline of pain catastrophizing behaviors will be measured at 6 week and 10 week

  6. Patient satisfaction

    Patient satisfaction will be evaluated with Global Rating of Change. No score is defined.

    Time frame: Measurement of changes from baseline of patient satisfaction will be measured at 6 week and 10 week

  7. Measurement of biomechanical characteristics of tissue

    Stiffness values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Stiffness values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.

    Time frame: Measurement of changes from baseline stiffness values of tissue will be measured at 6 week and 10 week]

  8. Measurement of biomechanical characteristics of tissue

    Tone values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Tone values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.

    Time frame: Measurement of changes from baseline tone values of tissue will be measured at 6 week and 10 week]

  9. Measurement of biomechanical characteristics of tissue

    Decrement values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Decrement values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.

    Time frame: Measurement of changes from baseline decrement values of tissue will be measured at 6 week and 10 week]

  10. Measurement of viscoelastic characteristics of tissue

    Creep values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Creep values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.

    Time frame: Measurement of changes from baseline creep values of tissue will be measured at 6 week and 10 week]

  11. Measurement of viscoelastic characteristics of tissue

    Relaxation time values of tissue will be measured with myotonPro B1 over the three most painful points in Control Group and Virtual Reality-1 Group. Relaxation time values of tissue will be measured with myotonPro B1 over the contralateral of the points reported as the three most painful points in Virtual Reality-2 Group.

    Time frame: Measurement of changes from baseline relaxation time values of tissue will be measured at 6 week and 10 week]

07

Study locations

1 site
  • Nilüfer kablan
    Istanbul, Kartal, Turkey (Türkiye)
08

References and documents

Publications

  • Adams LM, Turk DC. Psychosocial factors and central sensitivity syndromes. Curr Rheumatol Rev. 2015;11(2):96-108. doi: 10.2174/1573397111666150619095330. PubMed 26088211 ↗
  • Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, Fitzcharles MA, Paiva ES, Staud R, Sarzi-Puttini P, Buskila D, Macfarlane GJ. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019 Jun;20(6):611-628. doi: 10.1016/j.jpain.2018.10.008. Epub 2018 Nov 16. PubMed 30453109 ↗
  • Caneiro JP, Bunzli S, O'Sullivan P. Beliefs about the body and pain: the critical role in musculoskeletal pain management. Braz J Phys Ther. 2021 Jan-Feb;25(1):17-29. doi: 10.1016/j.bjpt.2020.06.003. Epub 2020 Jun 20. PubMed 32616375 ↗
  • Ciaramella A. Hypnotic analgesia in chronic pain: role of psychopathology and alexithymia. Am J Clin Hypn. 2023 Apr;65(4):299-313. doi: 10.1080/00029157.2022.2161868. Epub 2023 Feb 7. PubMed 36749869 ↗
  • de la Coba P, Montoro CI, Reyes Del Paso GA, Galvez-Sanchez CM. Algometry for the assessment of central sensitisation to pain in fibromyalgia patients: a systematic review. Ann Med. 2022 Dec;54(1):1403-1422. doi: 10.1080/07853890.2022.2075560. PubMed 35579545 ↗
  • Gholamrezaei A, Van Diest I, Aziz Q, Vlaeyen JWS, Van Oudenhove L. Controlled breathing and pain: Respiratory rate and inspiratory loading modulate cardiovascular autonomic responses, but not pain. Psychophysiology. 2021 Oct;58(10):e13895. doi: 10.1111/psyp.13895. Epub 2021 Jul 6. PubMed 34231231 ↗
  • Ichesco E, Puiu T, Hampson JP, Kairys AE, Clauw DJ, Harte SE, Peltier SJ, Harris RE, Schmidt-Wilcke T. Altered fMRI resting-state connectivity in individuals with fibromyalgia on acute pain stimulation. Eur J Pain. 2016 Aug;20(7):1079-89. doi: 10.1002/ejp.832. Epub 2016 Jan 15. PubMed 26773435 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2026, 23 months.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 23 months is above that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 18, 2024
StartActual
Aug 13, 2024
Primary completionActual
Aug 3, 2026was Jun 2026
CompletionActual
Aug 3, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 27, 2026
Primary completion
Jun 15, 2026→Aug 3, 2026 (actual)
Oct 27, 2026
Study completion
Aug 15, 2026→Aug 3, 2026 (actual)
Oct 27, 2026
Enrollment
39 (estimated)→36 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Completed
    Primary completion Jun 15, 2026→Aug 3, 2026 (now actual)
    Study completion Aug 15, 2026→Aug 3, 2026 (now actual)
    Enrollment 39 (estimated)→36 (actual)
    + 4 other changes: index terms, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06508385
Responsible party
Nilufer Kablan (Assoc. prof, Istanbul Medeniyet University) — Principal investigator
First posted
Jul 18, 2024
Start date
Aug 13, 2024
Primary completion
Aug 3, 2026
Completion
Aug 3, 2026
Last update
Oct 27, 2026

Study contacts

Nilüfer Kablan, PhD
principal investigator · İstanbul Medeniyet Üniversitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion